Pfizer Initiates Phase 1 Study on PF-07832837 for Atopic Dermatitis Treatment

Pfizer has initiated a Phase 1 clinical study to assess the safety and efficacy of PF-07832837, a potential treatment for atopic dermatitis. The study aims to evaluate the drug's safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy adults and those with moderate to severe atopic dermatitis. The study is ongoing, with recruitment and progress updates submitted on June 23, 2025. Successful results could boost Pfizer's position in the dermatological treatment market and potentially enhance investor confidence.

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) and its partner Angel Pharmaceuticals Ltd. (Angel Pharma) have received approval from the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) to initiate a Phase 1b/2 clinical trial of soquelitinib for the treatment of moderate-to-severe atopic dermatitis in China. The trial will be conducted by Angel Pharma and will study a 12-week dosing period of soquelitinib in patients with the condition.

Soquelitinib, an investigational oral small molecule drug that selectively inhibits ITK, is being developed by Corvus Pharmaceuticals for various cancer and immune diseases. The Phase 1b/2 trial will be randomized, double-blinded, and placebo-controlled, enrolling 48 patients with moderate-to-severe atopic dermatitis. The trial will evaluate two dosing cohorts of soquelitinib, each with three treatment arms, including placebo. The treatment period will be 12 weeks, with the principal investigator being Yuling Shi, M.D., Ph.D., a renowned dermatologist.

The trial builds on Corvus' ongoing Phase 1 trial and aims to expand clinical experience with soquelitinib in atopic dermatitis. Angel Pharma, a privately held biopharmaceutical company developing immune modulators in China, will be responsible for all expenses related to the development and commercialization of soquelitinib in the region. The trial is expected to begin enrolling patients in the third quarter of 2025, with data from the Phase 1b portion available in 2026.

Corvus remains on track with the development of soquelitinib for atopic dermatitis in the U.S., with ongoing patient enrollment in its Phase 1 extension cohort and plans to initiate a Phase 2 trial by the end of 2025. The successful completion of the Phase 1b/2 trial in China could provide valuable insights into the drug's efficacy and safety profile, potentially boosting Corvus' position in the dermatological treatment market and enhancing investor confidence.

References:
[1] https://www.biospace.com/press-releases/corvus-pharmaceuticals-announces-partner-angel-pharmaceuticals-received-ind-approval-for-a-phase-1b-2-clinical-trial-of-soquelitinib-in-china-for-the-treatment-of-atopic-dermatitis